On Feb. 6, 2017, the first clinical trial to study the effects of medical marijuana in the treatment of post-traumatic stress disorder in military veterans dispensed medical marijuana to its first veteran at the Scottsdale Research Institute in Phoenix, as reported by the Multidisciplinary Association for Psychedelic Studies, the clinical trial’s sponsor.
“As this is the first placebo-controlled trial of cannabis for PTSD, we are breaking important ground needed to identify improved treatment options for veterans with PTSD,” said Marcel Bonn-Miller, Ph.D., Coordinating Principal Investigator for the MAPS-sponsored study.
The clinical trial is taking place at two study sites, with Sue Sisley, M.D., leading the clinical trial at the Scottsdale Research Institute and Ryan Vandrey, Ph.D., leading the clinical trial at Johns Hopkins University in Baltimore.
Both study sites are still recruiting military veterans to participate in the clinical trial. Interested veterans in the Phoenix-area can contact email@example.com and those in the Baltimore-area can call (410) 550-0050.
MAPS has been able to fund its PTSD marijuana study via a $2.156 million research grant from the Colorado Department of Public Health and Environment.